Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 19Terminated 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Neoplasms by Site 1Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bronchial Neoplasms 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × napabucasin × Clear all
NCT02826161 2023-11-15

CanStem43L

Sumitomo Pharma America, Inc.

Phase 3 Terminated
4 enrolled 6 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02851004 2021-09-05

Special Combination of BBI608 and Pembrolizumab

National Cancer Center Hospital East

Phase 1/2 Terminated
55 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡